07 session he chaired entitled "ST Elevation Myocardial Infarction: The First 24 Hours." Dr. Smith: I'm Dr. Sidney Smith and with me is Dr. Elliott Antman, director of the Samuel A. Levine Cardiac ...

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.

The following is a summary of "Low-dose dobutamine stress myocardial contrast echocardiography for evaluating myocardial ...

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...

In patients with acute heart failure, it is unclear how body mass index affects clinical outcomes following acute myocardial infarction.

Researchers have observed that female patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) are more likely to ...

For over two decades, a ‘treatment-risk paradox’ has been described in older adults with cardiovascular disease, with ...

SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.

The US Food and Drug Administration has approved Tenecteplase as first FDA-approved stroke medication in nearly three decades ...